The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | DLL3: a promising target in neuroendocrine carcinomas
Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, shares insights into current and emerging treatment of neuroendocrine carcinomas. DLL3 is emerging as a promising target for treatment, with the DLL3/CD3-targeting bispecific T-cell engager obrixtamig showing strong efficacy in combination with chemotherapy. Trispecific antibodies, antibody-drug conjugates and CAR T-cell therapies are also showing promise in this area. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
